Covidien Patent Enforced Against China-Based Companies
NEW HAVEN, Conn.--(BUSINESS WIRE)--Covidien, a leading global provider of healthcare products, today announced that German customs authorities, in cooperation with Covidien, have seized quantities of imported surgical stapling products that copy Covidiens designs and infringe one of its patents. The government seizures collected infringing surgical stapling products that had been imported into the German market from two China-based companies.
"We are pleased that German authorities have found that the stapling products from these two companies should be removed from the German marketplace because of the infringement of our patent," said Scott Herring, Vice President, Endomechanical and Energy Division, Covidien. "This is a serious issue, for practitioners and patients, as well as for Covidien, and we will continue to vigorously protect our innovations and intellectual property."
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.